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Abstract
The ubiquitin protease pathway plays important role in human bone marrow-derived mesenchymal stem cell (hBMSC)
differentiation, including osteogenesis. However, the function of deubiquitinating enzymes in osteogenic
differentiation of hBMSCs remains poorly understood. In this study, we aimed to investigate the role of ubiquitin-
specific protease 53 (USP53) in the osteogenic differentiation of hBMSCs. Based on re-analysis of the Gene Expression
Omnibus database, USP53 was selected as a positive regulator of osteogenic differentiation in hBMSCs. Overexpression
of USP53 by lentivirus enhanced osteogenesis in hBMSCs, whereas knockdown of USP53 by lentivirus inhibited
osteogenesis in hBMSCs. In addition, USP53 overexpression increased the level of active β-catenin and enhanced the
osteogenic differentiation of hBMSCs. This effect was reversed by the Wnt/β-catenin inhibitor DKK1. Mass spectrometry
showed that USP53 interacted with F-box only protein 31 (FBXO31) to promote proteasomal degradation of β-catenin.
Inhibition of the osteogenic differentiation of hBMSCs by FBXO31 was partially rescued by USP53 overexpression.
Animal studies showed that hBMSCs with USP53 overexpression significantly promoted bone regeneration in mice
with calvarial defects. These results suggested that USP53 may be a target for gene therapy for bone regeneration.
Introduction
Bone homeostasis is regulated by the balance of osteo-
genesis (bone formation) and osteoclastogenesis (bone
resorption)1–3. The imbalance of these processes leads to
low bone density and deterioration of the bone matrix,
which increases the risk of skeletal disorders, such as
osteoporosis4. Osteoporosis causes serious socioeconomic
problems5,6. Several therapeutics have been developed to
maintain bone homeostasis7,8, including bone-forming
and antiresorptive compounds. However, these com-
pounds have serious side effects, including peptic ulcers,
atypical femur fractures, osteonecrosis of the jaws, and
increased risk of bone tumor9,10. Therefore, novel ther-
apeutic agents are urgently needed.
The ubiquitin-proteasome pathway (UPP) is an ATP-
dependent, reversible pathway that degrades target pro-
teins11. Up to 80% of all intracellular proteins are degra-
ded through the UPP. The reaction occurs through the
hierarchal transfer of ubiquitin-activating enzyme (E1),
ubiquitin-conjugating enzyme (E2), and ubiquitin ligase
(E3), resulting in target protein degradation11. Deubiqui-
tinating enzymes (DUBs) then remove ubiquitin chains
from a target protein, controlling the function and stabi-
lity of the protein12,13.
UPPs have important roles in the osteogenic differ-
entiation of human bone marrow-derived mesenchymal
stem cells (hBMSCs)14. Runt-related transcription factor 2
(RUNX2), a master transcription factor in osteogenesis,
interacts with smad ubiquitination regulatory factor 1
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(Smurf1) and Smurf2, E3 ligases, leading to the degrada-
tion of RUNX215. As an E3 ligase, WW domain-
containing E3 ubiquitin protein ligase 1 negatively reg-
ulates osteoblast differentiation targeting RUNX216. The
E3 ligase, Itch, also negatively regulates osteoblast func-
tion17. Accumulating evidence indicates that E3 ligases
play important roles in the regulation of osteogenesis in
hBMSCs18,19. However, few studies have addressed the
functions of DUBs in the osteogenic differentiation of
hBMSCs20,21.
Ubiquitin-specific peptidase 53 (USP53), a member of
the deubiquitinating enzyme family, contains a catalyti-
cally inactive ubiquitin-specific protease domain and is
expressed in cochlear hair cells22. Mice lacking Usp53
exhibit progressive hearing loss22; additionally, USP53 is
mutated in novel syndromic forms of cholestatic liver
disease in humans23. However, the functions of USP53
are unclear.
Accordingly, in this study, we identified USP53 as a
differentially expressed gene (DEG) in re-analysis of the
Gene Expression Omnibus (GEO) database and investi-
gated the roles of USP53 in osteogenic differentiation of
hBMSCs. We hypothesized that USP53 may positively
regulate the osteogenic differentiation of hBMSCs
in vitro and that local delivery of AAV2-USP53 to cal-
varial defects would thus enhance bone formation. Our
findings provide important insights into the potential
applications of AAV2-USP53-activated hBMSCs in gene
therapy for bone regeneration.
Results
Expression of upregulated DUBs during the osteogenic
differentiation of hBMSCs and selection of USP53 as a
DUB-associated molecule
Based on GEO datasets and previous studies24, com-
monly upregulated DUBs in hBMSC osteogenesis were
analyzed (Supplementary Table S1). From the selected
DUBs, USP53 was found to show the most marked
upregulation during the osteogenic differentiation of
hBMSCs. Next, we examined the relative mRNA and
protein levels of osteogenic markers during osteogenesis in
hBMSCs. The mRNA and protein expression levels of
osteogenic markers increased in the early phase of hBMSC
osteogenesis (days 3–7) and decreased during the late
phase of hBMSC osteogenesis (days 10–12; Supplementary
Fig. 1). Consistent with the database findings, USP53
mRNA and protein expression levels were increased in the
early phase and decreased in the late phase of osteogenesis
in hBMSCs (Fig. 1a, b). Thus, USP53 may regulate the
osteogenic differentiation of hBMSCs.
Knockdown of USP53 inhibited the osteogenic
differentiation of hBMSCs in vitro
We then investigated the roles of USP53 in the osteo-
genic differentiation of hBMSCs using short hairpin RNA
(shRNA) targeting USP53. Approximately 90% knock-
down efficiency was achieved (Supplementary Fig. 2a, b).
Additionally, knockdown of USP53 decreased ALP and
Alizarin Red S staining intensity as well as ALP activity
(Fig. 2a–d). The effects of USP53 knockdown on osteo-
genic differentiation were not attributable to cell viability
(Supplementary Fig. 3a, b). qRT-PCR and western blotting
revealed that osteogenic marker levels in USP53-
knockdown hBMSCs were decreased compared with
that in shMock-transfected cells (Fig. 2e, f). These results
suggested that knockdown of USP53 decreased the
osteogenic differentiation of hBMSCs.
Overexpression of USP53 promoted the osteogenic
differentiation of hBMSCs in vitro
To further examine the roles of USP53 in the osteo-
genic differentiation of hBMSCs, we prepared lentiviral
Fig. 1 Upregulation of USP53 during the osteogenic differentiation of hBMSCs. a Relative mRNA expression levels of USP53 during the
osteogenic differentiation of hBMSCs. HPRT was used for normalization. b Protein levels of USP53 during the osteogenic differentiation of hBMSCs.
Heat shock protein 90 (HSP90) was used as a loading control. USP53 protein expression was quantified using ImageJ. Day 0: undifferentiated hBMSCs.
Results are means ± SDs. ns: not significant, *P < 0.05, ***P < 0.001 by one-way ANOVA. n= 3.
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constructs expressing USP53 in hBMSCs. High over-
expression efficiency was confirmed in USP53-
overexpressing hBMSCs (Supplementary Fig. 2c, d).
Overexpression of USP53 enhanced ALP and Alizarin
red S staining intensity as well as ALP activity
(Fig. 3a–d). The effects of overexpression of USP53 on
osteogenic differentiation were not attributable to cell
viability (Supplementary Fig. 3c, d). qRT-PCR and
Fig. 2 USP53 knockdown inhibits the osteogenic differentiation of hBMSCs in vitro. a Alkaline phosphatase staining was performed in shMock-
or shUSP53-1-, 2-infected hBMSCs in osteogenic medium for 3 days. Scale bars, 200 μm. b Quantification of ALP activity. c Alizarin red S staining was
performed in shMock- or shUSP53-1-, 2-infected hBMSCs in osteogenic medium for 12 days. Scale bars, 200 μm. d Quantification of Alizarin red S
staining. e qRT-PCR analysis of osteogenesis-related genes on day 3 after osteogenic differentiation. f Immunoblot analysis of osteogenesis-related
genes on day 5 after osteogenic differentiation. Data were quantified using ImageJ. Results are means ± SDs. ns: not significant, **P < 0.01, ***P <
0.001, ****P < 0.0001 by one-way ANOVA. n= 3.
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Fig. 3 USP53 overexpression promotes the osteogenic differentiation of hBMSCs in vitro. a Alkaline phosphatase staining was performed in
control or USP53-infected hBMSCs in osteogenic medium for 3 days. Scale bars, 200 μm. b Quantification of ALP activity. c Alizarin red S staining
was performed in osteogenic medium for 12 days. Scale bars, 200 μm. d Quantification of Alizarin red S staining. e qRT-PCR analysis of
osteogenesis-related genes on day 3 after osteogenic differentiation. f Immunoblot analysis of osteogenesis-related genes on day 5 after
osteogenic differentiation. Data were quantified using ImageJ. Results are means ± SDs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by
unpaired two-tailed Student’s t-test. n= 3.
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western blot analysis revealed that osteogenic marker
expression levels in USP53-overexpressing hBMSCs
were upregulated compared with those in control cells
(Fig. 3e, f). Thus, USP53 positively regulated the osteo-
genic differentiation of hBMSCs.
USP53 regulated the osteogenic differentiation of hBMSCs
through Wnt/β-catenin signaling
A signaling pathway involving Wnt/β-catenin, trans-
forming growth factor-beta (TGF-β), bone morphogenetic
protein (BMP), parathyroid hormone-related protein
(PTHrP), and insulin-like growth factor (IGF) signaling
plays important roles in regulating RUNX2 expression.
Thus, western blot analysis was performed to evaluate the
expression of Wnt/β-catenin signal pathway mediators in
hBMSCs with overexpression or knockdown of USP53.
The levels of unphosphorylated β-catenin were higher in
hBMSCs overexpressing USP53 than in the control
(Fig. 4a). Conversely, the levels of unphosphorylated
β-catenin in USP53-knockdown hBMSCs were reduced
compared with those in shMock-transfected cells
(Fig. 4b). There were no significant differences in other
signaling pathways (Supplementary Figs. 4 and 5 and
Table S2).
To investigate whether USP53 promoted the osteo-
genesis of hBMSCs through the Wnt/β-catenin signaling
pathway, we examined the effects of a Wnt/β-catenin
activator (Wnt3a) and inhibitor (DKK1) in hBMSCs with
knockdown or overexpression of USP53. Inhibition of
the osteogenic differentiation capacity in the shUSP53
group was rescued in response to Wnt3a, an activator
of the Wnt pathway (Fig. 4c). Conversely, enhanced
osteogenic differentiation capacity in the USP53 over-
expression group was reduced in response to DKK1, an
inhibitor of the Wnt pathway (Fig. 4d), suggesting that
USP53 may be essential for the osteogenic differentiation
of hBMSCs through Wnt/β-catenin signaling. In vitro
ubiquitination assays showed that β-catenin degradation
was significantly reduced by USP53 overexpression in
a concentration-dependent manner, whereas down-
regulation of USP53 promoted the degradation of
β-catenin (Fig. 4e, f). Moreover, USP53 increased the
half-life of active β-catenin compared with that in the
control group (Fig. 4g). Taken together, these findings
suggested that USP53 acted as a deubiquitinase enzyme,
stabilizing β-catenin.
Identification of USP53 binding proteins and regulation of
β-catenin degradation by FBXO31 through the Skp1/Cul1/
F-box protein (SCF) complex
Immunoprecipitation (IP) and LC–MS/MS were per-
formed to identify proteins that interacted with USP53 in
the osteogenesis of hBMSCs (Supplementary Table S3).
Seven proteins were identified as interacting with USP53
during hBMSC osteogenesis, including F-box only protein
31 (FBXO31) (Fig. 5a). To examine whether USP53
interacted with FBXO31 in hBMSCs, co-IP and western
blotting were performed using wild-type and mutant
FBXO31 (myc-FBXO31ΔF), the latter of which harbored a
deletion of the F-box domain, which mediates binding to
Skp1 and Cul1. As shown in Fig. 5b, USP53 and FBXO31
bound with each other in hBMSCs. However, the FBXO31
mutant failed to interact with USP53, identifying FBXO31
as a novel binding partner of USP53.
FBXO31 is a candidate tumor-suppressor gene in breast,
ovarian, hepatocellular, and prostate cancers25 and acts as
a functional SCF-FBXO31 E3 ubiquitin ligase25,26. There-
fore, we examined the effects of FBXO31 on the osteo-
genic differentiation of hBMSCs by controlling the
expression of genes associated with osteogenesis. First, we
examined the mechanism through which FBXO31 regu-
lated the stability of β-catenin, a key mediator of the Wnt
signaling pathway27 and bone formation during osteogenic
differentiation28, using co-IP and western blot assays
with wild-type FBXO31 and myc-FBXO31ΔF. As shown in
Fig. 5b, FBXO31 specifically interacted with β-catenin,
Skp1, and USP53. These results were effectively reversed
by FBXO31 mutation (myc-FBXO31ΔF). Ectopic expres-
sion of FBXO31 or FBXO31 mutant at increasing con-
centrations in hBMSCs showed that FBXO31 significantly
decreased β-catenin levels in a concentration-dependent
manner; no changes were observed for the FBXO31
mutant (Fig. 5c, d). Moreover, FBXO31-mediated degra-
dation of β-catenin was significantly blocked in the pre-
sence of MG132 (a 26S proteasome inhibitor), indicating
that β-catenin stability was regulated at the post-
translational level by FBXO31 (Fig. 5e).
F-box proteins bind with Skp1 to form an SCF complex
through the F-box domain and bring their substrates to
the complex for ubiquitination29. Therefore, to determine
whether FBXO31 degraded β-catenin through the SCF
complex, wild-type and mutant FBXO31 were over-
expressed in hBMSCs. As shown in Fig. 5f, compared with
wild-type FBXO31, FBXO31 mutant did not reduce
β-catenin levels, indicating that FBXO31 degraded
β-catenin through the SCF complex. Then, we examined
whether FBXO31 regulated the transcriptional activity of
β-catenin during the osteogenesis of hBMSCs using TOP/
FOP assays. FBXO31 reduced the transcriptional activity
of β-catenin during the osteogenesis of hBMSCs; however,
no significant reduction was observed in the FBXO31
mutant during the same process (Fig. 5g). Finally,
β-catenin polyubiquitination was confirmed by ubiquiti-
nation assays. FBXO31 mutant caused FBXO31 to lose
the capability to promote β-catenin degradation (Fig. 5h).
These results demonstrated that FBXO31 interacted with
β-catenin and promoted the degradation of β-catenin
through the SCF complex.
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Fig. 4 USP53 regulates osteogenic differentiation in hBMSCs through Wnt/β-catenin signaling. a, b Expression levels of Wnt/β-catenin
signaling pathway mediators were investigated by immunoblotting in USP53-overexpressing (a) or -knockdown (b) hBMSCs in osteogenic medium
for 7 days. Data were quantified using ImageJ. c Immunoblot analysis of Wnt3a-induced osteogenic marker expression. Data were quantified using
ImageJ. d Immunoblot analysis of DKK1-induced osteogenic marker expression. Data were quantified using ImageJ. e Immunoblot analysis of
β-catenin-linked polyubiquitination with overexpression of USP53. β-Catenin ubiquitination (top panel) and protein expression assays (bottom panel)
were evaluated. f Immunoblot analysis of β-catenin-linked polyubiquitination with siUSP53. β-Catenin ubiquitination (top panel) and protein
expression assays (bottom panel) were evaluated. g hBMSCs were transfected with Flag-β-catenin overexpression plasmid and control or Flag-USP53
and then treated with cycloheximide (100 μg/mL) and Wnt3a. Immunoblots with active β-catenin protein at the indicated time points. n= 3.
Baek et al. Cell Death and Disease          (2021) 12:238 Page 6 of 15
Official journal of the Cell Death Differentiation Association
Next, we further investigated the effects of FBXO31 on
the osteogenic differentiation of hBMSCs. First, we
examined the effects of FBXO31 RNA interference on the
osteogenic differentiation potential of hBMSCs. As shown
in Fig. 5i, RNA interference of FBXO31 significantly
increased active β-catenin and osteogenic marker levels
compared with scrambled control siRNA. Conversely,
FBXO31 overexpression decreased active β-catenin levels,
Fig. 5 (See legend on next page.)
Baek et al. Cell Death and Disease          (2021) 12:238 Page 7 of 15
Official journal of the Cell Death Differentiation Association
resulting in reduced osteogenesis of hBMSCs. However,
this phenomenon was rescued after modulating the
expression of USP53 (Fig. 5j). These results demonstrated
that the FBXO31-mediated reduction of osteogenesis in
hBMSCs was significantly blocked in the presence
of USP53.
hBMSCs with AAV2-USP53 improved bone formation
in vivo
A mouse calvarial defect model was used to determine
the effects of AAV2-USP53-infected hBMSCs on bone
formation in vivo. Critical-size calvarial defects (5 mm in
diameter) were created and then covered with fibrin glue
mixed with AAV2-control-infected hBMSCs or AAV2-
USP53-infected hBMSCs (Fig. 6a). Eight weeks after sur-
gery, μCT images showed enhanced bone regeneration in
the AAV2-USP53-infected hBMSC group compared with
that in AAV2-control-infected hBMSCs (Fig. 6b). Quan-
tification of μCT images showed that the proportion of
bone volume per tissue volume (BV/TV) and bone surface
density in the AAV2-USP53-infected hBMSC group were
higher than those in the AAV2-control-infected hBMSC
group (Fig. 6c). Calvarial surface calcein staining and
mineral apposition rates were increased in the AAV2-
USP53-infected hBMSC group (Fig. 6d).
Next, to investigate new bone formation, we per-
formed M&T staining. The results showed that newly
formed bone in the AAV2-USP53-infected hBMSC
group was increased compared with that in the AAV2-
control-infected hBMSC group (Fig. 6e). Evaluation of
the expression of vimentin, a mesenchymal stem cell
marker, by IHC showed that vimentin expression was
increased in the AAV2-USP53-infected hBMSC group,
indicating that the newly regenerated bone originated
from the implanted hBMSCs (Fig. 6f). Next, we inves-
tigated the expression of osteocalcin (OCN), an impor-
tant marker of extracellular matrix mineralization, by
IHC analysis. The expression of OCN was higher in
the AAV2-USP53-infected hBMSC group than in the
AAV2-control-infected hBMSC group (Fig. 6g). Taken
together, these results demonstrated that AAV2-USP53-
infected hBMSCs had therapeutic effects on a calvarial
defect murine model.
USP53 expression was decreased in patients and mice with
osteoporosis
Osteoporosis is a disease that causes bones to become
weak without symptoms and increases the risk of broken
bones. To explore the relationships between USP53 and
osteoporosis, a GEO dataset (GSE35959)30 was analyzed.
The results showed that USP53 expression in BMSCs
from patients with osteoporosis was downregulated
compared with that in normal controls (Supplementary
Table S4). Furthermore, the roles of USP53 in osteo-
porosis were examined in an OVX mouse model to
induce estrogen deficiency-related osteoporosis. μCT
results showed that there was a significant reduction in
trabecular bone mass in OVX mice compared with that in
sham control mice (Fig. 7a). Next, we confirmed the
expression of CTX-1 in OVX mice by ELISA. The
expression of the bone resorption marker CTX-1 in OVX
mice was increased compared with that in sham control
mice (Fig. 7b). Moreover, the protein levels of USP53 in
bone sections from OVX mice were also lower than those
from sham mice, as confirmed by immunofluorescence
staining (Fig. 7c). Taken together, these results demon-
strated that USP53 expression was downregulated in
patients and mice with osteoporosis.
Discussion
Understanding the molecular mechanisms that regulate
bone homeostasis is essential for the development of
improved therapeutics to treat human skeletal disorders.
UPPs are required for the osteogenic differentiation of
hBMSCs14. Since USPs regulate cell cycle activity that is
involved in post-translational modification, it is crucial in
various diseases. Recent studies reported that USPs play
an important role in cancer progression. In case of USP2a,
(see figure on previous page)
Fig. 5 Identification of USP53 binding proteins and effects of FBXO31 on β-catenin degradation through the SCF complex. a Instantblue
staining of a co-IP mixture separated by SDS-PAGE. The indicated band was extracted for analysis. b hBMSCs were cotransfected with FLAG-β-catenin
with either myc-FBXO31 or myc-FBXO31ΔF for 48 h. Transfected cells were incubated with 10 μM MG132 for 6 h, and whole cells were lysed and
subjected to IP with anti-myc antibodies. Immunoprecipitates and input protein extracts (Pre-IP) were resolved in SDS-PAGE. c hBMSCs were
transfected with pCMV-myc or myc-FBXO31 for 48 h, and whole cell lysates were immunoblotted. d hBMSCs were transfected with pCMV-myc or
myc-FBXO31ΔF for 48 h, and whole-cell lysates were immunoblotted. e hBMSCs were transfected with the pCMV-myc or myc-FBXO31 for 48 h.
Transfected cells were then incubated with or without 10 μM MG132 for 6 h. Cell lysates were immunoblotted. f hBMSCs were transfected with
pCMV-myc, myc-FBXO31, and myc-FBXO31ΔF for 48 h. Cells were harvested and lysed, and whole-cell protein extracts were immunoblotted.
g β-Catenin transcriptional activity was measured on day 5 after induction of osteogenesis by TOP/FOP luciferase assays. h HEK293 cells were
transfected with the indicated plasmids for 48 h, treated with 10 μM MG132 for 6 h, lysed, subjected to IP with anti-HA antibodies, and
immunoblotted. i hBMSCs were transfected with negative control or FBXO31 siRNA for 5 days in osteogenic induction medium. Immunoblot analysis
was performed, and data were quantified using ImageJ. j hBMSCs were transfected with empty vector, FBXO31, or GFP-USP53 and then cultured with
osteogenic induction medium for 5 days. Immunoblot analysis was performed, and data were quantified using ImageJ. Results are means ± SDs.
ns: not significant, **P < 0.01 by one-way ANOVA. n= 3.
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Fig. 6 hBMSCs with AAV2-USP53 improved bone formation in vivo. a Experimental design of the mouse calvarial defect model. b Critical-size
calvarial defects (5 mm in diameter) in mice were treated with AAV2-control-infected hBMSCs or AAV2-USP53-infected hBMSCs in fibrin matrix with
PBS. Eight weeks after surgery, bone regeneration was measured by μCT. c Relative quantification of μCT analysis. d Histomorphometric analysis of
calvarial defects in mice. Arrows indicate the distance between double calcein labeling. Scale bars, 20 μm. Relative histomorphometric quantification
of the mineral apposition rate (MAR) is shown (right). e Representative images of M&T staining of calvarial bone sections in mice. Scale bars, 200 μm.
*New bone. f Immunohistochemistry analysis using an antibody against human vimentin and IgG control of calvarial bone sections in mice. Scale
bars, 20 μm. g Immunohistochemistry analysis of USP53 (phycoerythrin [PE]; red fluorescence) and OCN (fluorescein isothiocyanate [FITC]; green
fluorescence) with DAPI counterstaining of the calvarial defects in mice (left). Quantification of IHC analysis (right). Scale bars, 50 μm. Results are
presented as means ± SDs. ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA. n= 5 per group.
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it is overexpressed around 50% in human prostate cancers
and affects the invasion ability of prostate cells31. USP22 is
also upregulated in many cancer cells and activates the
proliferation, migration, and invasion of gastric cancer,
colorectal cancer, and breast cancer32–34. Another study
reported that USP4 is overexpressed in hepatocellular
carcinoma (HCC) tissues. And, USP4 increases progres-
sion of HCC through stabilization of cyclophilin A and
deubiquitination35. Recently, USP34 has been reported as
a positive regulator in osteogenic differentiation of
hBMSCs36. Additionally, in the study about USP53, it was
overexpressed in cervical cancer tissues and the inhibition
of USP53 reduced cancer cell arrest37. But, none of the
studies has reported about deubiquitinase enzyme which is
related to osteoporosis. Here, we found that USP53 posi-
tively regulated the osteogenesis of hBMSCs in vitro and
in vivo. Additionally, we confirmed that USP53 over-
expression promoted osteogenesis in hBMSCs by activat-
ing the Wnt/β-catenin signaling pathway in vitro and that
USP53 bound with FBXO31 during the osteogenic differ-
entiation of hBMSCs. Mechanistically, FBXO31 negatively
regulated the osteogenic differentiation of hBMSCs by
Fig. 7 USP53 levels decrease in an osteoporosis mouse model. a Sham or ovariectomy (OVX) surgery was performed on 6-week-old female mice.
Two months later, femoral trabecular bone mass was assessed by μCT. Scale bars, 50 μm. b Serum levels of the c-terminal telopeptide (CTX)-1 in sham
and OVX mice. c Immunohistochemistry analysis of USP53 (phycoerythrin [PE]; red fluorescence) and OCN (fluorescein isothiocyanate [FITC]; green
fluorescence) with DAPI counterstaining in sham-operated and OVX mice (left). Quantification of IHC analysis (right). Scale bars, 20 μm. Results are
means ± SDs. **P < 0.01 by an unpaired two-tailed Student’s t-test. n= 5–10 per group. d Diagram showing the molecular mechanism through
which FBXO31 and USP53 regulate the Wnt signaling mediator, β-catenin, during the osteogenic differentiation of hBMSCs.
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acting as an E3 ubiquitin ligase and degrading β-catenin.
Finally, USP53 expression was decreased in patients with
osteoporosis and in a mouse model of estrogen deficiency-
induced osteoporosis. Our findings provided further
insights into the roles of DUBs in the pathogenesis of
skeletal diseases and will be valuable for the development
of novel therapeutic strategies for bone regeneration in
tissue engineering.
We identified FBXO31 as a binding partner of USP53
and described its function in the osteogenesis of hBMSCs.
F-box proteins (FBPs) are core components of E3 ubi-
quitin ligases and determine substrate specificity for
degradation by protein targets38. Because the F-box motif
is essential for the interactions within the SCF complex,
this motif mediates the degradation of target proteins39.
FBXO31 is a member of the FBP family and interacts with
the SCF complex to form a functional SCF-FBXO31 E3
ubiquitin ligase, which regulates the ubiquitination of
target proteins, such as mouse double minute 2, cyclin D1,
forkhead box 1, chromatin licensing and DNA replication
factor 1, Slug, mitogen-activated protein kinase kinase 6,
and Par6c26,40. FBXO31 has been identified as a putative
tumor-suppressor gene in breast, ovarian, hepatocellular,
and prostate cancers. Its inactivation, due to hetero-
zygosity loss, is associated with several cancers41. Addi-
tionally, FBXO31 has been reported to interact with the
Skp1 protein26, and Cullin-1 and Roc-1 interact with myc-
FBXO31/HA-Skp126. Therefore, we hypothesized that
FBXO31 may regulate the osteogenic differentiation of
hBMSCs by modulating osteogenesis-related genes.
Because the overexpression of USP53 by lentivirus results
in enhanced osteogenic differentiation of hBMSCs
through the Wnt/β-catenin signal pathway, β-catenin may
be a target of the SCF-FBXO31 E3 ubiquitin ligase42,43.
Here, we confirmed that SCF-FBXO31 bound with
β-catenin and degraded β-catenin in hBMSCs. Moreover,
FBXO31 mutant did not promoted the proteasomal
degradation of β-catenin. Thus, FBXO31-SCF complex
interaction was removed in FBXO31 mutant. Moreover,
siFBXO31 enhanced the expression of active β-catenin
and promoted the osteogenesis of hBMSCs. Conversely,
overexpression of FBXO31 decreased active β-catenin and
RUNX2 levels, thereby suppressing hBMSC osteogenesis.
These results suggested that FBXO31 acted as an E3
ubiquitin ligase to degrade β-catenin, which then nega-
tively regulated hBMSC osteogenesis. Accordingly, the
FBXO31/β-catenin/USP53 axis may positively regulate
the osteogenic differentiation of hBMSCs (Fig. 7d).
To date, AAV is considered the most promising vector
for gene therapy. AAV is a nonenveloped parvovirus with a
single-stranded DNA genome 4.7 kb in length. This gen-
ome encodes four nonstrucutural replication proteins
(Rep78, Rep68, Rep52, and Rep40) and three structural
capsid proteins (viral proteins 1–3)44–46. The most
commonly used AAV serotype in bone biology is AAV2,
which is a potential carrier for target gene delivery in the
bone tissue47–50. Recently, AAV9 was classified as an
attractive vector for therapeutic gene delivery in bone tis-
sue44,51,52. In this study, we investigated the effects of
USP53 overexpressed in hBMSCs by delivering AAV2 in a
mouse calvarial defect model. These mice showed better
regeneration, as characterized by increased BV/TV, bone
surface density, and mineral apposition rates in comparison
with control mice. However, marked bone regeneration
was not observed in AAV2-USP53-infected hBMSCs.
These results may be related to the complete removal of
the periosteum, which has bone regeneration capacity.
We also analyzed the USP53 expression in hBMSCs of
elderly patients (79–94 years old) with osteoporosis using
a GEO dataset (GSE35959)30. Notably, USP53 expression
in patients with osteoporosis was downregulated com-
pared with that in normal controls. Similar results were
observed in OVX mice. Thus, these findings indicated
that USP53 may play important roles in the pathogenesis
of bone disorders such as osteoporosis.
In summary, USP53 acted as a positive regulator of
hBMSC osteogenic differentiation through Wnt/β-catenin
signaling. The FBP, FBXO31, a component of the SCF
complex, was shown to modulate the osteogenic differ-
entiation of hBMSCs by acting as an E3 ubiquitin ligase to
mediate the degradation of β-catenin. Intriguingly, USP53
was also shown to bind with the SCF ubiquitin ligase
complex to reduce the polyubiquitination of β-catenin
with FBXO31 dependently. Notably, transplantation of
AAV2-USP53-infected hBMSCs improved bone regen-
eration in a mouse calvarial defect model. Taken together,
our findings provide insights into the development of
novel therapeutic strategies for the treatment of bone
diseases. However, our findings are limited because we did
not examine whether USP53 mutation/deletion was pre-
sent in patients with osteoporosis. Further investigation is
needed to determine the roles of USP53 in osteoblast
lineages using Prx1-Cre;Usp53f/f, Sp7-Cre;Usp53f/f, or
Ocn-Cre;Usp53f/f mice.
Materials and methods
Cell culture and reagents
This study was approved by the Institutional Review
Board of Yonsei University College of Medicine (IRB no.
4-2017-0232). Human bone marrow aspirates were
obtained from the point 3 cm posterior to the anterior
superior iliac spine of 10 healthy adult donors with a
mean age of 35 years (range: 30–40 years). hBMSCs were
maintained in low-glucose Dulbecco’s modified Eagle’s
medium (DMEM-LG; Gibco BRL, Rockville, MD, USA)
with 10% fetal bovine serum (FBS; Gibco) and 1%
antibiotic-antimycotic solution (Gibco). Human embryo-
nic kidney 293 (HEK293) and 293FT cells were obtained
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from American Type Culture Collection (Manassas, VA,
USA). These cells were maintained in high-glucose
DMEM (DMEM-HG; Gibco) containing 10% FBS and
1% antibiotic-antimycotic solution (Gibco). DKK1 (R&D
Systems) was used at a concentration of 0.1 mg/mL in
hBMSCs53. Wnt3a (cat. no. 5036-WN; R&D Systems) was
used at a concentration of 10 ng/mL in hBMSCs54,55.
Microarray re-analysis
The mRNA expression profiles of hBMSCs in osteogenic
differentiation medium were found in GEO datasets
(https://www.ncbi.nlm.nih.gov/geo/) based on GSE1804324.
A web-based tool, GEO2R (http://www.ncbi.nlm.nih.gov/
geo/geo2r/) was used to analyze the DEGs by comparing
up-regulated DUBs during hBMSC osteogenesis at different
time points (day 0 versus days 1, 3, or 7). The cut-off value
was set as P < 0.05, log (fold change) > 2.0. The mRNA
expression profiles of hBMSCs from five patients with
osteoporosis (79–94 years old) were found in GEO datasets
based on GSE3595930 that contained a total of 9 samples
(hMSCs derived from 3 normal females, 1 normal male
donor, and 5 osteoporosis female patients). The cut-off
value was set as P < 0.05, log (fold change) < 0.5.
Osteogenic differentiation of hBMSCs
hBMSCs were seeded onto 12-well culture plates at a
density of 8 × 104 cells/well and then maintained for
10 days in osteogenic medium (DMEM-LG containing
10% FBS, 1% antibiotic-antimycotic solution, 100 nM
dexamethasone, 10mM β-glycerophosphate, and 50 μg/mL
ascorbic acid)53. The osteogenic medium was replenished
every 3 days. Alizarin red S and alkaline phosphatase (ALP)
staining procedures were performed as previously
described44.
Quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR)
Total RNA was isolated from cells using an RNeasy kit
(cat. no. 74106; Qiagen, Valencia, CA, USA). RNA (2 μg)
was then reverse transcribed using an Omniscript kit (cat.
no. 205113; Qiagen). qRT-PCR was performed using a
StepOnePlus Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA) and 2× qPCRBIO SyGreen
Mix (cat. no. PB20.12-05; PCR Biosystems) according to
the manufacturers’ guidelines. Primer sequences are listed
in Supplementary Table S5.
Western blotting
Total proteins were prepared from cells using passive
lysis buffer (cat. no. E194A; Promega, Madison, WI, USA),
and 30 μg of each sample was separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene difluoride
membranes. After blocking with tris-buffered saline with
Tween 20 containing 5% skim milk, blots were incubated
overnight at 4 °C with primary antibodies. All membranes
were then incubated with horseradish peroxidase-
conjugated secondary antibodies (1:5000; GenDEPOT)
for 1 h at room temperature. Finally, the western blots
were imaged using LAS 4000 (Fujifilm). Primary anti-
bodies are listed in Supplementary Table S6.
Plasmids and RNA interference
FLAG-HA-USP53 was gifted by Wade Harper (Addgene
plasmid #22606). FLAG-β-catenin was a gift from Eric
Fearon (Addgene plasmid #16828). pCMV-Myc (Clontech
plasmid #631604) was purchased from Clontech (TaKaRa,
Shiga, Japan). myc-F-box only protein 31 (FBXO31) and
myc-FBXO31ΔF were kind gifts from Prof. David F. Callen
(University of Adelaide and Hanson Institute, Adelaide,
Australia). The FBOX31 clone (untagged) was provided by
the Korea Human Gene Bank, Medical Genomics Research
Center (KRIBB, Daejeon, South Korea). Green fluorescent
protein (GFP)-RUNX2, myc-Ub, HA-Ub, and HA-Ub(K48)
were kindly provided by Prof. Jae-Hyuck Shim (University
of Massachusetts Medical School, Worcester, MA, USA).
Lentiviral control vector (pLenti-GIII-CMV-GFP-2A-Puro,
LV590) and lentiviral vector-USP53 (pLenti-GIII-CMV-
USP53-GFP-2A-Puro, LV353779) were purchased from
Applied Biological Materials (Richmond, BC, Canada).
Scramble negative control small interfering RNA (siRNA;
siRNA no. SN1002), USP53 siRNA (siRNA no. 54532), and
FBXO31 siRNA (siRNA no. 79791) were purchased from
Bioneer (Daejeon, South Korea).
Lentivirus production
293FT cells were transfected with USP53-overexpressing
lentivirus or USP53 shRNA along with packaging plasmid
(delta 8.9) and envelop plasmid (VSV-G) using Lipo-
fectamine LTX & Plus Reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
DMEM-LG supplemented with 10% FBS was changed 6 h
after transfection. The supernatants containing virus were
collected 24 and 48 h after initial transfection, filtered with
a 0.45-μm syringe filter (Millipore), separated into ali-
quots, and stored at -80 °C until use. hBMSCs were seeded
onto 6-well plates at a density of 1 × 105 cells/well and
transfected with purified lentiviruses for 24 h. Puromycin
(10 μg/mL; Sigma, St. Louis, MO, USA) was used for
selection, and stable lentivirus-infected hBMSCs were
used in experiments. Information on the lentiviral vectors
is provided in Supplementary Table S7.
Adeno-associated virus transduction
AAV blank control with GFP (serotype 2, 109 genome
copies [GC]/mL, AAV2-control, AAVP022) and AAV-
USP53 with GFP (serotype 2, 109 GC/mL, AAV2-USP53,
AAVP4915843) were purchased from Applied Biological
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Materials. For AAV infection, hBMSCs were seeded onto
12-well plates at a density of 8 × 104 cells/well. After 24 h,
hBMSCs were incubated with 40 μL AAV2-control and
AAV2-USP53 using X-tremeGENETM9 DNA transfection
reagent (Sigma). AAVs infected with hBMSCs were grown
to 80% confluence and then replated at a density of
1 × 105 cells in a 10-cm2 dish.
Immunoprecipitation analysis
Transfected cells were incubated with 10 μM MG132
(cat. no. M7749; Sigma) for 6 h, and whole cells were lysed
using nondenaturing lysis buffer (20 mM Tris-HCl [pH
8.0], 137mM NaCl, 0.5% Nonidet P40 with 2 mM ethy-
lenediaminetetraacetic acid [EDTA, pH 8.0], 1 mM phe-
nylmethylsulfonyl fluoride, and protease inhibitor). The
lysates were incubated with anti-myc or HA antibodies
overnight at 4 °C. Then, lysates were conjugated with
40 μL pre-washed protein A/G agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 4 h at 4 °C with
gentle rotation. Immunoprecipitates were eluted with
2× lane marker-reducing sample buffer (Thermo Fisher
Scientific). Eluates were separated using SDS-PAGE.
Liquid chromatography tandem mass spectrometry
(LC-MS/MS)
To investigate USP53-binding proteins in hBMSCs, the
cells were transfected with lentiviral control vector or
lentiviral vector-USP53 and cultured in osteogenic
induction medium for 4 days. The cells were then treated
with MG132 (10 μM) for 6 h, and hBMSCs were harvested
using passive lysis buffer (Promega). Total protein
(approximately 500 μg) was incubated with an antibody
against GFP (cat. no. sc-390394; Santa Cruz Biotechnol-
ogy) and IgG control (cat. no. 12-370; Milipore) at 4 °C
overnight. SDS-PAGE was performed, following which the
gels were stained with an InstantBlue staining kit (cat. no.
ISB1L; Sigma). Differential bands were collected for LC-
MS/MS, which was performed using a LTQ orbitrap mass
spectrometer (Thermo Electron, San Jose, CA, USA).
Luciferase reporter assays
hBMSCs were seeded onto 6-well plates at a density of
1 × 105 cells/well, and cells were transfected with 1 μg
pCMV-myc, myc-FBXO31, myc-FBXO31ΔF plus TOP-
flash (wild-type T cell factor binding site), or FOP-flash
(mutant T cell factor binding site) using Lipofectamine LTX
& Plus Reagent (Invitrogen) according to the manu-
facturer’s instructions. After 24 h, the cells were maintained
for 5 days in osteogenic induction medium. The cells were
analyzed using a simple dual-luciferase assay (Promega).
Protein degradation assay
hBMSCs were seeded at a density of 1 × 105 cells/well
onto 6-well plates and transfected with Flag-β-catenin and
control or Flag-USP53. Cells were cultured in the pre-
sence of Wnt3a. After 48 h, 100 μg/mL cycloheximide
(cat. no. C4859; Sigma) was added. Cells were harvested at
the indicated time points.
Animal experiments
The Committee on the Ethics of Animal Experiments of
Yonsei University College of Medicine approved all ani-
mal experiments and protocols (permit no. IACUC-2019-
0168). Fifteen male Institute of Cancer Research (ICR)
mice (8 weeks old) were anesthetized with zoletil
(30 mg/kg body weight; Virbac Laboratories) and rompun
(10 mg/kg body weight; Bayer Korea) by intraperitoneal
injection. After shaving the skull, an alcohol swab was
used before hair trimming. The skin was retracted.
Critical-sized calvarial bone defects (4 mm inside
diameter/5 mm outside diameter) were created using a
trephine burr (Shudent). The animals were divided into
three groups as follows: (1) fibrin gel only, (2) hBMSCs
(5 × 105) with AAV2-control group, and (3) hBMSCs
(5 × 105) with AAV2-USP53. Fibrin gel (20 μL; TISSEEL)
was mixed with hBMSCs and implanted into defects.
Finally, the defect site was closed with vicryl plus (Ethicon
3-0) and nylon (Dermalon 3-0). Metacam (1mg/kg) was
used as an analgesic. Mice were sacrificed 8 weeks after
surgery, and the skulls were harvested.
Micro-computed tomography (μCT) and histological
analysis
Murine skulls were fixed in 4% paraformaldehyde
(PFA) for 3 days, following which μCT was performed
using a Skyscan 1173 High Energy Micro-CT scanner
(Skyscan NV, Kontich, Belgium) with a 40–130 kV, 8W
X-ray source. For histological analysis, skulls or femurs
were decalcified with 5% formic acid (Sigma) or 0.5 M
EDTA for 1 week. Fixed specimens were then embedded
in paraffin blocks and cut into 4-μm-thick sections.
Sections were deparaffinized in xylene and serially
rehydrated in ethanol. Sections were sequentially
stained with Masson trichrome (M&T) staining and
immunohistochemistry (IHC). Primary antibodies are
listed in Supplementary Table S8. For, 3,3′-diamino-
benzidine tetrahydrochloride staining, we used a Dako
REAL EnVision Detection System (cat. no. K5007;
DAKO), and counterstaining was performed with
hematoxylin (cat. no. GHS-3; Sigma). A Zeiss LSM 700
confocal laser scanning microscope (Carl Zeiss Micro
Imaging GmbH, Jena, Germany) was used to visualize
images. For performing mouse calvarial bone histo-
morphometry, 25 mg/kg calcein (cat. no. C0875; Sigma)
dissolved in 2% sodium bicarbonate solution was sub-
cutaneously injected into mice at 4-day intervals (days 6
and 2 before sacrifice). Undecalcified skull samples were
fixed in 4% PFA for 3 days and then embedded in plastic
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resin blocks (methyl methacrylate) for obtaining bone
sections (7 μm).
Enzyme-linked immunosorbent assay (ELISA)
The Committee on the Ethics of Animal Experiments of
Yonsei University College of Medicine approved all ani-
mal experiments and protocols (permit no. IACUC-2020-
0045). Female sham-operated and ovariectomized (OVX)
mice (C57BL/6J, 6 weeks old) were purchased from Japan
SLC (Hamamatsu, Japan). After 8 weeks, the sham and
OVX mice were sacrificed, and serum was collected by
cardiac puncture. Mouse RatLaps (C-terminal telopeptide
type I collagen [CTX-1]; cat. no. AC-06F1; IDS) was used
according to the manufacturer’s recommendations to
measure serum level of CTX-1.
Statistical analysis
For each experiment, samples were analyzed at least in
triplicate. Results with P values less than 0.05 were con-
sidered statistically significant. All data are presented as
means ± standard deviations (SDs). No animals or samples
were excluded from the analysis. We first performed
Shapiro-Wilk normality tests for normal distributions of the
groups. If normality tests were passed, two-tailed, unpaired
Student’s t-tests were used for the comparisons between two
groups. For comparisons of three or four groups, we used
one-way analysis of variance (ANOVA) if normality tests
were passed, followed by Tukey’s multiple comparison tests
for all pairs of groups. GraphPad PRISM software (version
8.0; La Jolla, CA, USA) was used for statistical analysis.
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